Purpose: Crotoxin is the main neurotoxin of South American rattlesnake Crotalus durissus terrificus. The neurotoxic action is characterized by a presynaptic blockade. The purpose of this research is to assess the ability of crotoxin to induce temporary paralysis of extraocular and facial muscles in humans. Methods: Doses of crotoxin used ranged from 2 to 5 units (U), each unit corres ponding to one LD50. We first applied 2U of crotoxin in one of the extraocular muscles of 3 amaurotic individuals to be submitted to ocular evisceration. In the second stage, we applied crotoxin in 12 extraocular muscles of 9 patients with strabismic amblyopia. In the last stage, crotoxin was used in the treatment of blepharospasm in another 3 patients. Results: No patient showed any systemic side effect or change in vision or any eye structure problem after the procedure. The only local side effects observed we re slight conjunctival hyperemia, which recovered spontaneously. In 2 patients there was no change in ocular deviation after 2U crotoxin application. Limitation of the muscle action was observed in 8 of the 12 applications. The change in ocular deviation after application of 2U of crotoxin (9 injections) was in average 15.7 prism diopters (PD). When the dose was 4U (2 applications) the change was in average 37.5 PD and a single application of 5U produced a change of 16 PD in ocular deviation. This effect lasted from 1 to 3 months. Two of the 3 patients with blepharospasm had the hemifacial spasm improved with crotoxin, which returned after 2 months. Conclusions: This study provides data suggesting that crotoxin may be a useful new therapeutic option for the treatment of strabismus and blepharospasm. We expect that with further studies crotoxin could be an option for many other medical areas.
INTRODUCTION
The term strabismus appears initially on the manuscripts of Hi pocrates (460 377 BC). The word has Greek origin, with strabós mea ning misaligned or squinted. The treatment of the various types of strabismus has been improved all over the years. The importan ce of preventing amblyopia and the better understanding of the active and passive forces that coordinate ocular movements are unquestionable. On the XIX century, more precisely on October, 26 th , 1839, Johann Friedrich Dieffenbach, a general surgeon from Berlin, corrected one case of strabismus doing miotomy in a medial rectus muscle. From this day on, a new era of strabology has begun (1) . Graffe introduced the partial and controlled tenotomy, and also the ad vance of extraocular muscles on the treatment of strabismus (2) . Hummelsheim, in 1907, described a technique of transposition of the extraocular muscles to treat paralytic strabismus, experimentally caused in animals and, in 1908, used this technique on humans (3) . Several other techniques of extraocular muscle transpositions were subsequently described, such as O'Connor (1921) (4) , Jensen (1964) (5) , Knapp (1969) (6) , Almeida (1976) (7) , Carlson and Jampolsky (1979) (8) and Brooks et al., (2000) (9) . The first citation in literature about pharmacological treatment of strabismus was done in 1973 (10) . The authors studied the effects of intramuscular injection of diisopropyl fluorophosphate (DFP), Abungarotoxin (snake toxin), botulinum toxin type A and alcohol. They observed that DFP and alcohol were very toxic and did not show the desired effect of muscle paralysis. The bungarotoxin, a neurotoxin of a snake from India, showed no toxicity in the concentrations that were injected, and it caused a temporary paralysis of extraocular muscles in monkeys. However, this effect was too short, and did not reach the proposed objectives. The botulinum toxin type A caused a temporary paralysis of extraocular muscles in monkeys, with no side effects. After this animal experimentation, they concluded that botulinum toxin type A was appropriate for injection in humans, to treat strabismus (12) . Other therapeutic applications of botulinum toxin, in ophthalmology, were studied right after. The use of this drug in essential blepharospasm treatment is, nowadays, the treatment of choice (12, 13) . Botulinum toxin is a neurotoxin, with molecular weight of 900 KDa. This complex has eight serotypes, classified from A to G, with similar structures and functions. All types are synthesized with one single branch of polypeptides, of approximately 150 KDa. After the sepa ration of the toxin, to obtain only type A, the 150 KDa polypeptides branch transforms into a molecule with two branches, one with 100 KDa, and the other with 50 KDa. The heavy chain is responsible for the high affinity of the neurotoxin to the presynaptic termination, thus allowing its entrance into the cell. The light branch is responsible for the lesions of membrane proteins that do the binding of vesicles containing acetylcholine in the interior of the nerve terminal. These damaged proteins are called SNAP25, and they have a molecular weight of 25 KDa. After the damage of these proteins, the acetylcho line release is impaired (14) . Other toxins that act in the neuromuscular joint could also be useful in the treatment for strabismus and other diseases in which botulinum toxin type A has been successfully used. The neurotoxin crotoxin due to its high toxicity could have a similar effect to botulinum toxin type A. Crotoxin is the main neurotoxin in the poison of South American rattlesnake, Crotalus durissus terrificus. This species is found in the Brazilian territory, and it is considered one of the most dangerous snakes of the occident, due to the high toxicity of its poison (15) . The poison of the South American rattlesnake, usually, does not cause any local reaction but produces three main systemic altera tions: neurotoxic, myotoxic and blood clotting. The neurotoxic ac tivity is characterized by the blockade of neurotransmitter release of the peripheral neuron at the motor endplate, causing muscular paralysis. The clinical profile is composed of discrete local manifesta tion and systemic intoxication that can be severe. Muscle paralysis caused by the neurotoxin effect of rattlesnake poison can produce acute breathing insufficiency, which can lead to death. The specific treatment is done with anticrotalic serum, or with the specific por tion of antiophidic serum (16) . Crotoxin blocks the release of acetylcholine at the presynapsis. This blocking occurs in three stages. At the first stage acetylcholine release diminishes, possibly related to binding of the toxin to the re ceptor at the neural membrane. This stage lasts around five minutes. At the second stage, occurs an increase of neurotransmitter release, due to the increase of calcium concentration in peripheral motor neuron cytoplasm. This stage takes between ten to thirty minutes. At the third stage, occurs the progressive reduction until the complete blockade in acetylcholine release (17, 18) . Based on the crotoxin effect as a neuromuscular blocker, we ini tially studied its effect on inducing temporary muscle paralysis in animals. With the good results obtained, we have decided to analyze its effect in humans.
RESUMO
The objective of this study was to evaluate the efficacy of crotoxin to induce facial and extraocular muscle paralysis in human beings, analyzing also its duration and possible side effects.
METHODS
This study was carried out at the 
Crotoxin preparation
The extraction of rattlesnake poison, the purification of crotoxin and the LD50 research were all done at FUNED.
Determination of LD50
The toxicity of this solution was determined through LD50 in mice with 18 to 22 grams, through intraperitoneal injection. Female and male mice were used in groups of eight animals per dose, with reading after 48 hours. We defined that one LD50 of crotoxin would correspond to one unit (U). Estimated LD50 for a 70 kg person would be equivalent to 3,500 LD50 obtained with mice.
The most frequently used botulinum toxin type A (BTXA), is Bo tox®, and one unit of it corresponds to 1 LD50. In treating strabismus, we usually use 5 to 10 units in each extraocular muscle. In blepha rospasm are used 25 to 50 units, and in bigger muscles (e.g., lower limbs), 100 U may be used.
Definition of subjeCts for researCh
Gender, social class, and skin color have not influenced the selec tion of individuals for this research. All individuals were 18 years old or up. They fulfilled prerequisites and were invited to participate in the project and, those that accepted, signed a free informed consent, approved by the Research Ethics Committee/Investigational Review Board of the Federal University of Minas Gerais.
Individuals injected with crotoxin were followedup with oph thal mological and clinical exams, in order to observe possible local and systemic side effects. On the first stage of the study, three indivi duals with amaurosis (blindness) in one eye, to be submitted to evis ceration for ocular prosthesis, were invited to participate in this study (Group 1). All individuals were admitted to São Geraldo Hospital for followup. Two units of crotoxin (2 LD50) were injected in the medial rectus muscle of the atrophic eye. As there were no significant side effects, crosseyed individuals were selected, with no restriction of eye movements (group 2), with low vision in one eye (n=9). Crotoxin effects on extraocular muscles were evaluated through eye move ments (version) and ocular alignment measured through corneal reflex (Krimsky's method). The injection of crotoxin was done using a sound eletromyograph of Allergan brand, model 90016. The injection was done into the extraocular muscle, with a 37 mm x 27 G electrode needle, model 91079 (Allergan). Crotoxin concentration was of 2U in a 0.1 ml solution.
On the third stage of this study, three individuals with essential blepharospasm were selected, (group 3). The effect of crotoxin was evaluated, observing the improvement of symptoms, and also the characteristic signs of the disease.
RESULTS
Group 1 2U of crotoxin were injected in the medial rectus mus cle of the atrophic eye of three male individuals. It was observed that only one patient showed mild conjunctival hyperemia at the site of the injection, which improved spontaneously in two days. No systemic symptoms related to crotoxin application were observed.
Group 2 We did 12 applications in 9 crosseyed patients (Table 1) , six were females. No systemic effects were observed, and there was no alteration of sight or eye structure. We only observed mild con junctival hyperemia in one patient and complaints of pain or muscle pulling sensation at the site of the injection in three patients. No local or systemic medication was used after the injection of crotoxin. The side effects improved spontaneously in all cases. In 8 of 12 patients, it was observed a limitation in ocular movement in the field of action of the treated muscle, varying from 1 to 4, in a scale from 1=25% and 4=100%. In all cases there was progressive and total recovery of ocular movements after varying periods of time. The improvement of ocular deviation with 2U of crotoxin (nine injections) was in average 15.7 prism diopters (PD), but in two patients there was no change in deviation. With a dose of 4U (two injections) there was an average correction of 37.5 PD. In the single injection of 5U of crotoxin, we observed an improvement of only 16 PD in ocular deviation, probably due to extravasation of crotoxin during the injection. Ocular align ment alteration was maintained for up to three months. Examples: figures 1 to 4.
Group 3 Crotoxin was injected into 3 female patients with essential blepharospasm. All patients have already been submitted to botulinum toxin injections. Two patients had improved of the he mifacial spasms, which returned intermittently after 2 months. One patient had no significant improvement after crotoxin injection. Two patients complained of discrete local pain, which improved sponta neously after two days.
DISCUSSION
In the first study about strabismus treatment with botulinum to xin type A (BTXA), Scott 12 To ease the analysis and comparison, we describe our results in a similar way to the initial study of Scott about BTXA (12) (Tables 2 and 3 ). Analyzing the results, we believe that the ideal dose of croto xin to be injected into extraocular muscles is 5U diluted in 0.1 mL solution. In injections done with 4U in 0.2 mL and 5U in 0.25 mL, the greater volume of solution increased the extravasation of the An analysis of the current knowledge about the effects of botuli num toxin in many types of strabismus is necessary, because crotoxin would be indicated in the same cases.
Application of BTXA into extraocular muscles is usually done through transconjunctival injection at the physician's office. BTXA is mainly indicated for treatment of horizontal strabismus (esotropia more than exotropia), but particularly in cases of sixth nerve paralysis. It can also be used for cases of third and fourth nerves paralysis, in vertical deviations and thyroid orbitopathy (19) . Final success in injection of BTXA is, most of the times, preceded by a hypercorrection, associated with a movement limitation on the field of action of the injected muscle (20) . In our study 8 of 12 crotoxin ap plications caused reduction of rotation into field of muscle injected.
The use of BTXA for treatment of small and medium angle stra bismus was effective in a study conducted with 97 patients, with in jection into one or both eyes. The indexes of therapeutic success, with deviation lower than 10 PD after three months of followup were: 57.1% (unilateral BTXA injections) and 68.4% (bilateral BTXA injections) and 72.4% (surgery). Differences were not statistically sig nificant among the percentages of correction of ocular deviation and the index of therapeutic success among the three groups studied (14) . The injection of BTXA without using an eletromyograph (EMG) done in 40 children with different types of convergent strabismus has shown to be effective, with an index of complications comparable to those procedures done with EMG orientation. The use of forceps, specially developed for botulinum application into extraocular muscles has also shown to be effective as an alternative to the use of EMG (21) . The use of BTXA for treating convergent strabismus in patients with brain paralysis has shown to be effective with a sin gle injection for 47.1% of 17 patients studied. Side effects were: sub conjunctival hemorrhage, transitory vertical deviation and transitory ble pharoptosis (22) . In cases of sixth nerve paralysis, it must be considered if it is a re cent case (less than 6 months), or chronic case (more than 6 months) and whether the involvement is total (paralysis) or partial (paresis). Researchers found good results in treatment of acute sixth nerve pa ralysis, believing that by stopping or avoiding medial rectus muscle contracture, there would be a better recovery (23) . However, some studies have shown that the results in spontaneous recovery of sixth nerve palsy and in patients treated with BTXA were not statistically significant. With these results, BTXA success for treating sixth nerve paralysis must be interpreted with caution (24) . However, we believe that botulinum toxin must be applied to medial rectus muscle of every patient with recent paralysis of abducens nerve, particularly if it is of traumatic nature, to avoid contracture of the antagonist muscle and ease the surgical procedure, if it becomes necessary in the future.
The injection of BTXA to treat strabismus is an adequate option to many patients that do not want to be submitted to additional surgery. The most common complication of BTXA in treatment of strabismus is ptosis, probably due to spread of the toxin to orbital tissues. Asking the patient to stay seated right after the injection can diminish this side effect. A vertical deviation after the injection of BTXA into horizontal muscles can also occur (25) . An inadvertent in traocular injection of BTXA was reported and the patient had retinal detachment, treated with laser photocoagulation. Initially there was some loss of vision; however, after 2 days it returned to 6/6, remaining stable for 5 years. This occurrence supports studies with animals indi cating that the injection of BTXA into the vitreous does not damage intraocular tissues (26) . BTXA has been used to treat many types of strabismus. Well con ducted prospective studies are necessary to define in which types of strabismus BTXA can be used to achieve better results than those of traditional surgery.
New studies must be done in order to increase knowledge on the efficacy and safety of crotoxin in humans.
CONCLUSIONS
As our results were similar to Scott's initial study, and as we did not observe any significant side effects, we believe crotoxin can be a new therapeutic option to many areas of medicine which currently are using botulinum toxin.
